Fred Martin
Disciplined Growth Investors
Fred Martin Redhill Biopharma Ltd stake
total: 241
Disciplined Growth Investors RDHL trades
- Total transactions:
- 16
- New positions:
- 1
- Sold out:
- 1
- Added:
- 7
- Reduced:
- 7
- Held since:
- 2018 Q3
- Held for:
- 16 quarters
- Latest activity:
- 2022 Q3
According to 2026 Q2 report, Fred Martin doesn't hold any Redhill Biopharma Ltd (RDHL) shares. To date, the estimated cost basis is nearly $240.57 for "buy" trades and estimated average "sell" price is $77.64. Disciplined Growth Investors first purchased RDHL in 2018 Q3, initially acquiring 836 shares. Since the initial investment in Redhill Biopharma Ltd (RDHL), Disciplined Growth Investors has made 15 more transactions.
When did Fred Martin sell Redhill Biopharma Ltd (RDHL)?
Fred Martin sold off the entire Redhill Biopharma Ltd (RDHL) position in 2022 Q3.
When did Fred Martin buy Redhill Biopharma Ltd (RDHL)?
Fred Martin first invested in Redhill Biopharma Ltd (RDHL) in 2018 Q3 at the reported quarter-end price of $352.93 per share.
What's the cost basis of Disciplined Growth Investors's RDHL stake?
The estimated cost basis for Redhill Biopharma Ltd (RDHL) stake is around $240.57 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $240.57
- Weighted AVG sell price:
- $77.64
Fred Martin's historical trades in Redhill Biopharma Ltd
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q3
|
0.00%
|
0
|
$34.79
|
|
-100% (-20,266.15)
|
-0.02%
|
|
2022 Q2
|
0.02%
|
20,266.15
|
$34.79
|
$705,000
|
-58.43% (-28,483.9)
|
-0.02%
|
|
2022 Q1
|
0.11%
|
48,750.05
|
$100.80
|
$4,914,000
|
+0.74% (+360.32)
|
+0%
|
|
2021 Q4
|
0.10%
|
48,389.73
|
$103.20
|
$4,994,000
|
-2.07% (-1,022.17)
|
-0%
|
|
2021 Q2
|
0.26%
|
49,411.9
|
$275.20
|
$13,598,000
|
+8.09% (+3,697.22)
|
+0.02%
|
|
2021 Q1
|
0.27%
|
45,714.68
|
$292.79
|
$13,385,000
|
-9.89% (-5,015.2)
|
-0.03%
|
|
2020 Q4
|
0.32%
|
$323.20
|
-3.90% (-2,056.4)
|
|||
|
2020 Q3
|
0.51%
|
$408.80
|
-0.30% (-159.15)
|
|||
|
2020 Q2
|
0.34%
|
$267.99
|
+24.25% (+10,333.2)
|
|||
|
2020 Q1
|
0.18%
|
$181.19
|
-7.98% (-3,696.82)
|
|||
|
2019 Q4
|
0.19%
|
$242.80
|
+61.78% (+17,683.7)
|
|||
|
2019 Q3
|
0.15%
|
$281.60
|
+0.40% (+113.75)
|
|||
|
2019 Q2
|
0.14%
|
$260.00
|
-0.82% (-236.78)
|
|||
|
2019 Q1
|
0.17%
|
$332.40
|
+0.61% (+173.35)
|
|||
|
2018 Q4
|
0.13%
|
$222.01
|
+3,318.68% (+27,739.18)
|
|||
|
2018 Q3
|
0.00%
|
$352.93
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.